JPWO2019209896A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019209896A5
JPWO2019209896A5 JP2020559472A JP2020559472A JPWO2019209896A5 JP WO2019209896 A5 JPWO2019209896 A5 JP WO2019209896A5 JP 2020559472 A JP2020559472 A JP 2020559472A JP 2020559472 A JP2020559472 A JP 2020559472A JP WO2019209896 A5 JPWO2019209896 A5 JP WO2019209896A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
substituted
nhs
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559472A
Other languages
English (en)
Japanese (ja)
Other versions
JP7351850B2 (ja
JP2021522249A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028823 external-priority patent/WO2019209896A1/en
Publication of JP2021522249A publication Critical patent/JP2021522249A/ja
Publication of JPWO2019209896A5 publication Critical patent/JPWO2019209896A5/ja
Priority to JP2023149057A priority Critical patent/JP2024001030A/ja
Application granted granted Critical
Publication of JP7351850B2 publication Critical patent/JP7351850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559472A 2018-04-25 2019-04-24 Nlrp3修飾因子 Active JP7351850B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023149057A JP2024001030A (ja) 2018-04-25 2023-09-14 Nlrp3修飾因子

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862662240P 2018-04-25 2018-04-25
US62/662,240 2018-04-25
US201862764818P 2018-08-16 2018-08-16
US62/764,818 2018-08-16
US201962825044P 2019-03-28 2019-03-28
US62/825,044 2019-03-28
PCT/US2019/028823 WO2019209896A1 (en) 2018-04-25 2019-04-24 Nlrp3 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149057A Division JP2024001030A (ja) 2018-04-25 2023-09-14 Nlrp3修飾因子

Publications (3)

Publication Number Publication Date
JP2021522249A JP2021522249A (ja) 2021-08-30
JPWO2019209896A5 true JPWO2019209896A5 (hr) 2022-04-25
JP7351850B2 JP7351850B2 (ja) 2023-09-27

Family

ID=66677224

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559472A Active JP7351850B2 (ja) 2018-04-25 2019-04-24 Nlrp3修飾因子
JP2023149057A Pending JP2024001030A (ja) 2018-04-25 2023-09-14 Nlrp3修飾因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023149057A Pending JP2024001030A (ja) 2018-04-25 2023-09-14 Nlrp3修飾因子

Country Status (19)

Country Link
US (1) US12037344B2 (hr)
EP (2) EP3784670B1 (hr)
JP (2) JP7351850B2 (hr)
KR (1) KR102711180B1 (hr)
CN (2) CN112074516A (hr)
AU (1) AU2019261582A1 (hr)
BR (1) BR112020021539A2 (hr)
CA (1) CA3097865A1 (hr)
CL (1) CL2020002719A1 (hr)
CO (2) CO2020013155A2 (hr)
ES (1) ES2971122T3 (hr)
IL (1) IL278173A (hr)
MX (1) MX2020011234A (hr)
NZ (1) NZ769136A (hr)
PE (1) PE20210160A1 (hr)
SG (1) SG11202010463TA (hr)
TW (1) TW202014420A (hr)
WO (1) WO2019209896A1 (hr)
ZA (1) ZA202007307B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
EP4135844A1 (en) * 2020-04-16 2023-02-22 Incyte Corporation Fused tricyclic kras inhibitors
JP2023523756A (ja) 2020-04-30 2023-06-07 ヤンセン ファーマシューティカ エヌ.ベー. 新規なトリアジノインドール化合物
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
CN116390923A (zh) * 2020-08-21 2023-07-04 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
WO2022037631A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
EP3984535A1 (en) * 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
CN114539095A (zh) * 2020-11-26 2022-05-27 乐凯化学材料有限公司 3-(4-羟基-3-甲氧基-苯基)-2-氰基-2-丙烯酸乙酯的制备方法
US12077539B2 (en) 2021-03-22 2024-09-03 Incyte Corporation Imidazole and triazole KRAS inhibitors
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンkras阻害剤
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US20090075980A1 (en) 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US20070259907A1 (en) 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
US20080193468A1 (en) 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
JP2010535844A (ja) 2007-08-14 2010-11-25 ノバルティス アーゲー Gabaアルファリガンドとしてのピラゾロキノリンおよびピラゾロナフチリジン誘導体
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
CN103608040B (zh) 2011-04-20 2017-03-01 米迪缪尼有限公司 结合b7‑h1和pd‑1的抗体和其他分子
ES2527188T3 (es) 2011-09-26 2015-01-21 Sanofi Derivados de pirazolquinolinona, su preparación y su uso terapéutico
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104418867B (zh) * 2013-08-26 2016-12-28 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的化合物,其制备方法和用途
CN112457403B (zh) 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP4001311A1 (en) 2014-07-09 2022-05-25 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
MY194225A (en) 2015-03-13 2022-11-22 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
WO2016199943A1 (en) 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
KR20180040706A (ko) 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
CN105523955B (zh) * 2015-12-14 2018-08-17 北京嘉林药业股份有限公司 化合物及其在制备药物中的用途
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
MX2018012249A (es) * 2016-04-19 2019-02-07 Innate Tumor Immunity Inc Moduladores de nlpr3.
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
AU2018301681B2 (en) 2017-07-14 2022-07-14 Innate Tumor Immunity, Inc. NLRP3 modulators
WO2019206799A1 (en) 2018-04-25 2019-10-31 Bayer Aktiengesellschaft Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides

Similar Documents

Publication Publication Date Title
JP2020508302A5 (hr)
JPWO2019209896A5 (hr)
JP2020125349A5 (hr)
Khafif et al. Primary branchiogenic carcinoma
US20090005406A1 (en) Cancer Treatment Method
ES2640787T3 (es) Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JPWO2019199792A5 (hr)
WO2007143483A2 (en) Combination of pazopanib and lapatinib for treating cancer
JPWO2019191470A5 (hr)
JP2020515571A5 (hr)
CA2511843A1 (en) Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
JPWO2019150305A5 (hr)
JP2019522681A5 (hr)
CN105120868A (zh) 组合治疗
JP2019070012A5 (hr)
BR122020016659B1 (pt) moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
JP2020527139A5 (hr)
JP2019527231A5 (hr)
JP2018062523A5 (hr)
KR20140138984A (ko) 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 기타 항종양 화합물과의 조합
JPWO2020037091A5 (hr)
JPWO2020037092A5 (hr)
JP2021505551A5 (hr)
JP2004510761A5 (hr)